STOCK TITAN

Sensus Healthcare Inc - SRTS STOCK NEWS

Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.

Overview of Sensus Healthcare Inc

Sensus Healthcare Inc is a specialized medical device company that has dedicated over a decade to the development of non-invasive treatment solutions using proprietary superficial radiation therapy (SRT) technology. This innovative treatment method is designed for both oncological and non-oncological skin conditions, including various forms of non-melanoma skin cancers and conditions such as keloids, offering a safe and cost-effective alternative to surgical procedures.

Core Technology and Treatment Solutions

The company utilizes a proprietary low energy x-ray radiation system that underpins its SRT technology. This method enables precise targeting of skin lesions while minimizing damage to surrounding tissues. The approach is rooted in extensive research and development, ensuring that each device deployed not only aligns with current clinical standards but also supports a streamlined treatment process. The primary devices in the company’s portfolio are designed to simplify the treatment procedure while ensuring efficacy and patient safety.

Business Model and Revenue Generation

Sensus Healthcare Inc generates revenue primarily through the sale of its specialized SRT treatment devices alongside an associated service program. The revenue model is based on direct transactions with hospitals, oncology centers, and dermatology practices, particularly in the United States. The company’s sales approach integrates product delivery with ongoing support, positioning Sensus as a comprehensive service provider within the medical device industry. This dual-focus on advanced technology and customer service ensures that clients receive not only the equipment but also the necessary operational expertise to maximize treatment outcomes.

Market Position and Industry Significance

Operating within the competitive realm of medical devices, Sensus Healthcare Inc has carved out a niche by focusing on non-invasive superficial radiation therapy. The technology addresses a clear need in the treatment of skin conditions by reducing the potential risks and complications associated with more invasive procedures. With increasing emphasis on patient safety and cost-effectiveness in healthcare, the company’s offerings are well-positioned to provide value within hospital oncology and dermatology departments. Its emphasis on targeted radiation treatment distinguishes its operational approach from other modalities available in the market.

Operational Focus and Customer Base

The company's operational framework is built around delivering effective treatment solutions through both its high-quality devices and a robust support program. The customer base includes major healthcare providers such as hospital oncology departments and specialized dermatology practices. By prioritizing reliability and clinical efficacy, Sensus Healthcare sustains trust within the medical community, ensuring continuous adoption of its technology in outpatient treatment settings.

Clinical Impact and Safety

At the heart of Sensus Healthcare Inc's offerings is a strong commitment to patient safety and treatment efficacy. The non-invasive SRT technique minimizes the need for surgical intervention, thereby reducing recovery times and potential risks associated with more invasive treatments. This clinical approach not only enhances patient outcomes but also supports operational efficiency in healthcare settings by offering a streamlined alternative that aligns with modern treatment protocols.

Competitive Landscape and Differentiation

Sensus Healthcare Inc operates in a dynamic industry where differentiation is critical. The company sets itself apart through its exclusive focus on superficial radiation therapy, a technology with a clear evidential basis in decades of research and clinical application. Although facing competition from traditional and emerging treatment modalities, Sensus leverages its research-backed technology and dedicated service programs to maintain a distinct foothold in the market. Expertise in both technological innovation and customer service elevates its competitive profile as a trusted provider in the non-invasive medical device segment.

Conclusion

In summary, Sensus Healthcare Inc is a specialized medical device entity that combines technological innovation with secure, non-invasive treatment options. Its use of superficial radiation therapy not only underscores advances in medical device innovation but also reflects the company's commitment to enhancing patient care in the treatment of skin conditions. This comprehensive approach, integrating advanced product development with dedicated service programs, positions Sensus Healthcare as a valued participant in a complex and critical segment of healthcare technology.

Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) introduces its new 'Fair Deal Agreement' for SRT-100 Vision™ IG-SRT in one-on-one meetings, aiming to enhance customer value and establish a recurring revenue model. The company will engage with institutional investors at the 36th Annual Roth conference to discuss this program and recent achievements at the American Academy of Dermatology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
conferences
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) successfully launched its new 'Fair Deal Agreement' for the SRT-100 Vision™ at the AAD 2024 Annual Meeting. The agreement expands access to their image-guided superficial radiotherapy technology for dermatology offices, generating record sales leads. The company's collaboration with CureRays enhances patient safety and regulatory compliance, positioning them as industry leaders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.58%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. (SRTS) announces fourth quarter revenues of $12.6 million, a three-fold increase sequentially, reflecting ongoing customer adjustment to macroeconomic conditions. The company introduces a recurring revenue model for the SRT-100 Vision™ (IG-SRT) to address dermatologist demand and ended the year with $23.1 million in cash and cash equivalents, and no debt. The company also showcased the full line of SRT systems for treating non-melanoma skin cancer at the Fall Clinical 2023 dermatology conference and engaged CureRays to provide oversight and supervision for Sensus’ dermatology customers involved with the recurring revenue model and to ensure patient safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.3%
Tags
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) has been issued a new patent by the USPTO for a radiotherapy mobile and wireless device workflow management system. The patent covers systems and methods for treating patients with a radiotherapy system combining high-frequency ultrasound and optical imaging data. This technology is a treatment-planning system that fuses a radiation therapy device with a high-frequency ultrasound (the SRT-100 Vision) to guide clinicians in creating treatment plans. The patent also covers scheduling patient appointments, detecting medical equipment status, and communicating information on status to a service engineer. This new patent adds to Sensus Healthcare's valuable intellectual property portfolio and ensures protection for their innovative products for years to come.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. announces a collaboration with CureRays, a radiation oncology specialist organization, to research new indications for Sensus' superficial radiotherapy (SRT and IG-SRT) to include inflammatory diseases. CureRays will also provide oversight and supervision for Sensus' dermatology customers to ensure patient safety and regulatory compliance. The collaboration aims to broaden the market for Sensus' products, starting with arthritis. CureRays is led by Dr. Mohammad K. Khan and Dr. Clayton Hess, who are focused on radiation treatments for patients, radiation consulting for physicians, and the conduct of clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.72%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces the retirement of Samuel O'Rear from the Board of Directors and the appointment of Michael J. Sardano as a Director. The company expresses gratitude to O'Rear for his dedicated service and welcomes Sardano, highlighting his contributions to the company's milestones. O'Rear reflects on his 50 years of professional experiences in the healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 8, 2024, to discuss the financial results for the fourth quarter and full year 2023, along with a business update and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
conferences earnings
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces preliminary unaudited financial results for the three and 12 months ended December 31, 2023. The company expects to report revenue for the fourth quarter of 2023 of more than $12 million, with full-year revenue expected to exceed $23 million. They also achieved their guidance to ship more than 60 SRT systems during 2023. The company experienced a strong uptick in business during the fourth quarter despite customer impact from inflation and interest rates in the first three quarters of 2023. Sensus Healthcare plans to announce full financial results and hold an investment community conference call on February 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.32%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces financial results for the three and nine months ended September 30, 2023, reflecting lower revenues due to seasonality and macroeconomic conditions. The company reported revenues of $3.9 million, net loss of $1.5 million, and $20.5 million in cash and cash equivalents. The financial results were impacted by lower superficial radiotherapy (SRT) unit sales and lower sales to a large customer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.41%
Tags
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on November 9, 2023, at 4:30 p.m. Eastern time to discuss the financial results for Q3 2023. The call will include a business update and discussion on recent and upcoming milestones. Participants can pre-register for the call to receive a unique dial-in number. The call will be webcast live and a telephone replay will be available until December 9th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences earnings

FAQ

What is the current stock price of Sensus Healthcare (SRTS)?

The current stock price of Sensus Healthcare (SRTS) is $4.58 as of April 10, 2025.

What is the market cap of Sensus Healthcare (SRTS)?

The market cap of Sensus Healthcare (SRTS) is approximately 73.1M.

What is the primary focus of Sensus Healthcare Inc?

Sensus Healthcare Inc specializes in developing and manufacturing non-invasive superficial radiation therapy devices for treating both oncological and non-oncological skin conditions.

How does Sensus Healthcare generate its revenue?

The company primarily generates revenue through direct sales of its specialized treatment devices and associated service programs to hospital oncology centers and dermatology practices.

What skin conditions are treated with the company's technology?

Their technology is used for treating non-melanoma skin cancers such as basal cell and squamous cell carcinoma, as well as non-cancerous conditions like keloids.

What distinguishes Sensus Healthcare's technology from traditional treatment options?

The company’s proprietary low energy x-ray radiation system offers a non-invasive, cost-effective, and targeted approach, reducing the need for surgical interventions and minimizing damage to surrounding tissues.

Who typically uses Sensus Healthcare's treatment devices?

The primary users are hospitals, oncology departments, and dermatology practices, especially in the U.S., where the non-invasive treatment options provide significant clinical advantages.

How does Sensus Healthcare position itself against competitors?

By leveraging extensive research and a unique focus on superficial radiation therapy, Sensus Healthcare differentiates itself through its commitment to safe, efficient, and non-invasive treatment solutions that are tailored to specific skin conditions.
Sensus Healthcare Inc

Nasdaq:SRTS

SRTS Rankings

SRTS Stock Data

73.07M
13.57M
17.75%
30.71%
5.13%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON